XLO Xilio Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XLO

Price (delayed)

$8.27

Market cap

$49.48M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.55

Enterprise value

-$96.03M

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 35
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 37

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is ...

Highlights
XLO's equity has surged by 106% since the previous quarter
XLO's quick ratio has soared by 85% YoY and by 38% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://xiliotx.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of XLO

XLO stock price

How has the Xilio Therapeutics stock price performed over time
Intraday
1.53%
1 week
-2.93%
1 month
-0.72%
1 year
-11.27%
YTD
-7.7%
QTD
-1.66%

Financial performance

How have Xilio Therapeutics's revenue and profit performed over time
Revenue
$53.48M
Gross profit
$53.48M
Operating income
-$42.24M
Net income
-$31.3M
Gross margin
100%
Net margin
-58.5%
Xilio Therapeutics's net margin has soared by 90% YoY and by 27% from the previous quarter
The operating margin has surged by 87% year-on-year and by 18% since the previous quarter
Xilio Therapeutics's net income has increased by 42% YoY and by 11% from the previous quarter
XLO's operating income is up by 26% year-on-year

Price vs fundamentals

How does XLO's price correlate with its fundamentals

Growth

What is Xilio Therapeutics's growth rate over time

Valuation

What is Xilio Therapeutics stock price valuation
P/E
N/A
P/B
0.66
P/S
2.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.8
Xilio Therapeutics's EPS has soared by 78% YoY and by 39% from the previous quarter
XLO's equity has surged by 106% since the previous quarter
XLO's price to book (P/B) is 57% lower than its 5-year quarterly average of 1.5
Xilio Therapeutics's revenue has increased by 22% QoQ
The stock's price to sales (P/S) is 20% less than its last 4 quarters average of 3.1

Efficiency

How efficient is Xilio Therapeutics business performance
Xilio Therapeutics's ROS has soared by 90% YoY and by 27% from the previous quarter
Xilio Therapeutics's return on assets has surged by 67% YoY and by 20% QoQ
The return on equity has surged by 62% since the previous quarter and by 55% year-on-year

Dividends

What is XLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XLO.

Financial health

How did Xilio Therapeutics financials performed over time
The total assets is 80% higher than the total liabilities
XLO's quick ratio has soared by 85% YoY and by 38% QoQ
XLO's current ratio has soared by 83% YoY and by 39% from the previous quarter
Xilio Therapeutics's debt is 91% less than its equity
XLO's equity has surged by 106% since the previous quarter
The company's debt to equity has shrunk by 88% YoY and by 55% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.